Mode
Text Size
Log in / Sign up
N/A N=41 Randomized Single-blind Treatment

Computer-Based Treatment for Social Anxiety Disorder

Social Anxiety Disorder

Enrolled (actual)
41
Serious AEs
0.0%
Results posted
Aug 2020
Primary outcome: Primary: Change in Percent Dwell Time on Threat Faces — 20.7; 27.1 percentage of dwell time on threat faces

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
computer-based treatment (Behavioral)
Age
Adult · 18+ yrs
Sex
All
Sponsor
New York State Psychiatric Institute
Primary completion
Mar 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Percent Dwell Time on Threat Faces
20.7; 27.1
PRIMARY
Change in Total Score of Liebowitz Social Anxiety Scale (LSAS)
23.68; 22.38
SECONDARY
Change in Total Score of Social Phobia Inventory (SPIN)
17.7; 10.1
SECONDARY
Change in Total Score of Quality of Life Enjoyment & Satisfaction Questionnaire
-8.8; -4.8
SECONDARY
Change in Total Score of the Revised Social Anhedonia Scale
1.7; 1.8
SECONDARY
Change in Total Score of the Snaith Hamilton Pleasure Scale
2.2; -1.0
SECONDARY
Change in Total Score of the Hamilton Rating Scale for Depression - 17 Item Version
1.8; 1.8
SECONDARY
Clinical Global Impression-Change Scale
2.8; 2.7

Summary

The present study is an open trial that seeks to examine the feasibility, acceptability, mechanism, and efficacy of a recently developed computer-based therapy in individuals with social anxiety disorder (SAD)

Eligibility Criteria

Inclusion Criteria

  • Males and females between the ages of 18 and 60
  • Current primary diagnosis of SAD
  • Score of at least 50 on the Liebowitz Social Anxiety Scale (Self-rated version)
  • Fluent in English and willing and able to give informed written consent and participate responsibly in the protocol
  • Normal or corrected-to-normal vision

Exclusion Criteria

  • Present or past psychotic episode, psychotic disorder, schizophrenia, schizoaffective disorder, or bipolar disorder
  • Current severe depression
  • Suicidal ideation or behavior
  • Current diagnosis of posttraumatic stress disorder, obsessive-compulsive disorder, bipolar disorder, manic episode or tic disorder
  • Current or past organic mental disorder, seizure disorder, epilepsy or brain injury
  • Current unstable or untreated medical illness
  • Severe alcohol use disorder, severe cannabis use disorder, and any severity of other substance use disorder (except nicotine use disorders allowed)
  • Use of psychiatric medication in the past month other than a stable dose of selective serotonin reuptake inhibitors (SSRIs) for a least 3 months
  • Any concurrent cognitive behavioral therapy; other psychotherapy that was initiated in the past 3 months
  • Pregnancy, or plans to become pregnant during the period of the study - will be assessed by urine
  • Contraindication to MRI scanning:
  • Paramagnetic metallic implants or devices contraindicating magnetic resonance imaging or any other non-removable paramagnetic metal in the body (e.g. pacemaker, paramagnetic metallic prosthesis, surgical clips, shrapnel, necessity for constant medicinal patch, some tattoos)
  • Being unable to tolerate the scanning procedures (i.e., severe obesity, claustrophobia)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03415022). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search